Literature DB >> 12557049

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Giovanni Paganelli1, Marco Chinol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12557049     DOI： 10.1007/s00259-002-1090-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  Cloning and characterization of Scavidin, a fusion protein for the targeted delivery of biotinylated molecules.

Authors:  Pauliina Lehtolainen; Anna Taskinen; Johanna Laukkanen; Kari J Airenne; Sanna Heino; Maarit Lappalainen; Kirsi Ojala; Varpu Marjomäki; John F Martin; Markku S Kulomaa; Seppo Ylä-Herttuala
Journal:  J Biol Chem       Date:  2001-12-12       Impact factor: 5.157

2.  Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Authors:  P L Weiden; H B Breitz; O Press; J W Appelbaum; J K Bryan; S Gaffigan; D Stone; D Axworthy; D Fisher; J Reno
Journal:  Cancer Biother Radiopharm       Date:  2000-02       Impact factor: 3.099

3.  The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy.

Authors:  G Paganelli; M Chinol; M Maggiolo; A Sidoli; A Corti; S Baroni; A G Siccardi
Journal:  Eur J Nucl Med       Date:  1997-03

4.  Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin.

Authors:  G Paganelli; C Grana; M Chinol; M Cremonesi; C De Cicco; F De Braud; C Robertson; S Zurrida; C Casadio; S Zoboli; A G Siccardi; U Veronesi
Journal:  Eur J Nucl Med       Date:  1999-04

5.  Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha.

Authors:  M Moro; M Pelagi; G Fulci; G Paganelli; P Dellabona; G Casorati; A G Siccardi; A Corti
Journal:  Cancer Res       Date:  1997-05-15       Impact factor: 12.701

6.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging.

Authors:  M Guttinger; F Guidi; M Chinol; E Reali; F Veglia; G Viale; G Paganelli; A Corti; A G Siccardi
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

8.  Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy.

Authors:  G Paganelli; R Orecchia; B Jereczek-Fossa; C Grana; M Cremonesi; F De Braud; N Tradati; M Chinol
Journal:  Eur J Nucl Med       Date:  1998-09

Review 9.  The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

10.  Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Authors:  C Grana; M Chinol; C Robertson; C Mazzetta; M Bartolomei; C De Cicco; M Fiorenza; M Gatti; P Caliceti; G Paganelli
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640
View more
  14 in total

1.  The TNM classification of breast cancer: need for change.

Authors:  Paolo Arnone; Stefano Zurrida; Giuseppe Viale; Silvia Dellapasqua; Emilia Montagna; Paola Arnaboldi; Mattia Intra; Umberto Veronesi
Journal:  Updates Surg       Date:  2010-10

Review 2.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

3.  Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice.

Authors:  Weibo Cai; Alireza Ebrahimnejad; Kai Chen; Qizhen Cao; Zi-Bo Li; David A Tice; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-03       Impact factor: 9.236

4.  Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma.

Authors:  Gui-Ping Li; Hui Zhang; Cheng-Mo Zhu; Jian Zhang; Xu-Feng Jiang
Journal:  World J Gastroenterol       Date:  2005-10-28       Impact factor: 5.742

5.  Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.

Authors:  Guozheng Liu; Shuping Dou; Jiang He; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02       Impact factor: 9.236

6.  Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor.

Authors:  Guozheng Liu; Jiang He; Shuping Dou; Suresh Gupta; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09       Impact factor: 9.236

7.  Pretargeted radioimmunotherapy for hematologic and other malignancies.

Authors:  Roland B Walter; Oliver W Press; John M Pagel
Journal:  Cancer Biother Radiopharm       Date:  2010-04       Impact factor: 3.099

Review 8.  An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.

Authors:  Marlein Miranda Cona; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  World J Methodol       Date:  2013-12-26

9.  Cancer Imaging and Therapy with Bispecific Antibody Pretargeting.

Authors:  David M Goldenberg; Jean-Francois Chatal; Jacques Barbet; Otto Boerman; Robert M Sharkey
Journal:  Update Cancer Ther       Date:  2007-03

10.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.